RxDoctor Payments Data

Krystyna Solarewicz, MD

Internal Medicine · Chicago, ILNPI 1134149727

Payments from drug & device makers

$1,114in general payments, 2019–2025

Across 18 payments — averaging $61.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$350
  • Teva Pharmaceuticals USA, Inc.$205
  • Sun Pharmaceutical Industries Inc.$159
  • Sumitomo Pharma America, Inc.$125
  • Acadia Pharmaceuticals Inc$119
  • Neurocrine Biosciences, Inc.$94
  • plus $61 from 2 others

What the payments were for

  • Food & beverage$1,114100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,114 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$285,638
Medicare patients
549
Services billed
1,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,023$282,402
XifaxanRifaximin59$89,453
XareltoRivaroxaban281$75,430
TrulicityDulaglutide82$61,716
Invega SustennaPaliperidone Palmitate19$60,788
FarxigaDapagliflozin Propanediol127$40,243
OzempicSemaglutide30$30,813
NuplazidPimavanserin Tartrate11$30,434
JardianceEmpagliflozin88$29,017
EntrestoSacubitril/Valsartan86$24,544
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$24,216
MyrbetriqMirabegron108$23,013
Spiriva HandihalerTiotropium Bromide35$19,706
Atorvastatin Calcium1,005$17,168
AbrysvoRsv Vacc, Pref A And Pref B/Pf53$16,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invega Sustenna$16$136,218300 claims
Acadia Pharmaceuticals IncNuplazid$119$30,43411 claims
Sumitomo Pharma America, Inc.Gemtesa$125$10,06146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →